Inventor · disambiguated record
Clark E. Tedford
Also filed as: TEDFORD CLARK E
25 granted patents·30 pending applications·383 citations·filing 1993–2024
96Inventor score
Top patents by PatentIndex Score
55 records- 0196US9475885B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2015·Granted Oct 25, 2016·15 cites·31 claims
- 0296US8652477B2Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2010·Granted Feb 18, 2014·61 cites·18 claims
- 0396US7919094B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2006·Granted Apr 5, 2011·86 cites·21 claims
- 0495US12336937B2Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissueLUMITHERA INC·Filed 2020·Granted Jun 24, 2025·3 cites·26 claims
- 0595US8840893B2Methods for treating conditions associated with MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2011·Granted Sep 23, 2014·36 cites·12 claims
- 0693US9855246B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2016·Granted Jan 2, 2018·9 cites·15 claims
- 0793US9486406B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2015·Granted Nov 8, 2016·10 cites·13 claims
- 0893US9066856B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2013·Granted Jun 30, 2015·15 cites·16 claims
- 0992US10219944B2Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatmentsLUMITHERA INC·Filed 2015·Granted Mar 5, 2019·15 cites·20 claims
- 1091US10881550B2Multi-wavelength phototherapy systems and methods for the treatment of damaged or diseased tissueLUMITHERA INC·Filed 2015·Granted Jan 5, 2021·12 cites·23 claims
- 1191US9011860B2Compositions for inhibiting MASP-2 dependent complement activationDUDLER THOMAS·Filed 2012·Granted Apr 21, 2015·20 cites·24 claims
- 1289US2025032452A1Stable preservative-free mydriatic and anti-inflammatory solutions for injectionRAYNER INTRAOCULAR LENSES LTD·Filed 2024·Application pending·0 cites
- 1388US6448282B11H-4(5)-substituted imidazole derivativesGLIATECH INC·Filed 2000·Granted Sep 10, 2002·29 cites·4 claims
- 1486US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1583US10596037B2Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatmentsLUMITHERA INC·Filed 2019·Granted Mar 24, 2020·3 cites·23 claims
- 1683US2024092938A1Compositions for inhibiting masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1781US11884742B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2019·Granted Jan 30, 2024·0 cites·14 claims
- 1875US12133842B2Stable preservative-free mydriatic and anti-inflammatory solutions for injectionRAYNE INTRAOCULAR LENSES LTD·Filed 2021·Granted Nov 5, 2024·0 cites·10 claims
- 1973US11613589B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted Mar 28, 2023·0 cites·13 claims
- 2073US2024076408A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 2172US6008240A2-(1H-4(5)-imidazoyl) cyclopropyl derivativesGLIATECH INC·Filed 1997·Granted Dec 28, 1999·17 cites·24 claims
- 2270US10683367B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2018·Granted Jun 16, 2020·0 cites·33 claims
- 2370US2020190215A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2019·Application pending·0 cites
- 2468US2020040104A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2019·Application pending·0 cites
- 2568US2020315844A1Devices and methods for non-invasive multi-wavelength photobiomodulation for ocular treatmentsLUMITHERA INC·Filed 2020·Application pending·0 cites
- 2667US5990317A2-(1H-4(5)-imidazoyl) cyclopropyl compoundsGLIATECH INC·Filed 1996·Granted Nov 23, 1999·11 cites·15 claims
- 2767US2010074899A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2009·Application pending·0 cites
- 2864US10047165B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2016·Granted Aug 14, 2018·0 cites·9 claims
- 2964US2018291111A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 3064US2018085349A1Stable preservative-free mydriatic and anti-inflammatory solutions for injectionOMEROS CORP·Filed 2017·Application pending·0 cites
- 3163US6166060A1H-4(5)-substituted imidazole derivativesGLIATECH INC·Filed 1997·Granted Dec 26, 2000·19 cites·24 claims
- 3262US2013266559A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2013·Application pending·0 cites
- 3362US2023391889A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2023·Application pending·0 cites
- 3462US2015064176A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2014·Application pending·0 cites
- 3561US2014205598A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2014·Application pending·0 cites
- 3660US5652258A2-(4-imidazoyl) cyclopropyl derivativesGLIATECH INC·Filed 1995·Granted Jul 29, 1997·8 cites·4 claims
- 3760US2018291112A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 3859US2016272727A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 3959US2021040229A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2020·Application pending·0 cites
- 4058US5486526AHistamine H3 -receptor antagonists and therapeutic uses thereofUNIV TOLEDO·Filed 1993·Granted Jan 23, 1996·13 cites·9 claims
- 4157US2017233493A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2016·Application pending·0 cites
- 4256US2017233494A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2016·Application pending·0 cites
- 4355US2017166660A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 4453US12390658B2Methods for treating ocular diseaseLUMITHERA INC·Filed 2018·Granted Aug 19, 2025·0 cites·20 claims
- 4553US2011020337A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2010·Application pending·0 cites
- 4653US2014056873A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2013·Application pending·0 cites
- 4752US2006035889A1Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonistsTEDFORD CLARK E·Filed 2005·Application pending·0 cites
- 4845US2003069295A1Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesityGLIATECH INC·Filed 2001·Application pending·0 cites
- 4944US2021059858A1Methods for preventing and treating ocular diseaseUNIV OF WISCONSIN MILWAUKEE RESEARCH FOUNDATION INC·Filed 2020·Application pending·0 cites
- 5043US2006035883A1Novel serotonin receptor ligands and their uses thereofTEDFORD CLARK E·Filed 2005·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Clark E. Tedford files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →